Patent News:
Wird dieses Unternehmen das nächste BioNTech sein?
Anzeige
ACCURAY WKN: A0MKWM ISIN: US0043971052 Kürzel: XEJ Forum: Aktien Thema: Hauptdiskussion
1,615 EUR
+0,31 %+0,005
17. Jun, 07:41:05 Uhr,
Lang & Schwarz
Kommentare 248
Summer.76,
26. Mär 19:14 Uhr
0
https://www.prnewswire.com/news-releases/new-data-from-two-clinical-studies-indicate-high-risk-and-recurrent-prostate-cancers-can-be-effectively-treated-in-5-days-using-the-accuray-cyberknife-system-302099017.html
Summer.76,
21.02.2024 16:39 Uhr
0
https://www.nasdaq.com/articles/three-reasons-to-retain-accuray-aray-stock-in-your-portfolio
Summer.76,
13.02.2024 17:30 Uhr
0
Roth/MKM sets $9 stock target on Accuray, bullish on market expansion
https://m.uk.investing.com/news/stock-market-news/rothmkm-sets-9-stock-target-on-accuray-bullish-on-market-expansion-93CH-3335248
Summer.76,
31.01.2024 22:41 Uhr
0
Accuray GAAP EPS of -$0.10 misses by $0.05, revenue of $107.2M beats by $0.53M
https://seekingalpha.com/news/4060915-accuray-gaap-eps-of-0_10-misses-0_05-revenue-of-107_2m-beats-0_53m
• Accuray press release (NASDAQ:ARAY): Q2 GAAP EPS of -$0.10 misses by $0.05.
• Revenue of $107.2M (-6.6% Y/Y) beats by $0.53M.
• The company is reaffirming guidance for fiscal year 2024 as follows:
• Total revenue is expected in the range of $460 million to $470 million, vs. consensus of $463.17M, representing a year-over-year growth range of 3 to 5 percent.
• Adjusted EBITDA for fiscal year 2024 is expected in the range of $27 million to $30 million.
Summer.76,
31.01.2024 22:41 Uhr
0
https://investors.accuray.com/news-releases/news-release-details/accuray-reports-fiscal-2024-second-quarter-financial-results
Accuray Reports Fiscal 2024 Second Quarter Financial Results
19% Order Growth YOY; 8% Service Revenue Expansion; Confirms FY24 Guidance
Henderson,
02.01.2024 23:09 Uhr
0
.
Summer.76,
07.11.2023 22:08 Uhr
0
Accuray Reports Fiscal 2024 First Quarter Financial Results
https://investors.accuray.com/news-releases/news-release-details/accuray-reports-fiscal-2024-first-quarter-financial-results
Company Achieves 8% Revenue Growth, Reiterates FY 2024 Guidance
Summer.76,
26.10.2023 18:56 Uhr
0
https://www.massdevice.com/accuray-lays-off-nearly-6-of-global-workforce/
Summer.76,
04.10.2023 16:33 Uhr
0
Accuray (ARAY) Positioned for Growth: Buy Rating Supported by Chinese Market Expansion, New Product Launches, and Strong Financial Projections
https://markets.businessinsider.com/news/stocks/accuray-aray-positioned-for-growth-buy-rating-supported-by-chinese-market-expansion-new-product-launches-and-strong-financial-projections-1032677267
Summer.76,
04.10.2023 16:31 Uhr
0
https://www.benzinga.com/pressreleases/23/10/n35072403/accuray-announces-approval-of-the-tomo-c-radiation-treatment-delivery-system-by-chinas-national-me
Summer.76,
02.10.2023 14:02 Uhr
0
Accuray and Limbus AI Unveil Online Adaptive Therapy Solution for the Radixact® System at American Society for Radiation Oncology (ASTRO) Annual Meeting
https://investors.accuray.com/news-releases/news-release-details/accuray-and-limbus-ai-unveil-online-adaptive-therapy-solution
...Cenos is designed to enable medical care teams to quickly and efficiently make adjustments, if necessary, to a treatment plan while the patient is still on the treatment table. ...
K
KrisenFest,
16.08.2023 8:57 Uhr
0
.
Summer.76,
15.08.2023 19:39 Uhr
0
https://finance.yahoo.com/news/accurays-aray-treatment-options-boosted-133000149.html
Robo1976,
10.08.2023 5:54 Uhr
0
👀
Summer.76,
10.08.2023 5:35 Uhr
0
Accuray Receives FDA Clearance for VitalHold™ on the Radixact® System; Breast Cancer Treatment Option Will Also Be Available in the EU Market
https://www.prnewswire.com/news-releases/accuray-receives-fda-clearance-for-vitalhold-on-the-radixact-system-breast-cancer-treatment-option-will-also-be-available-in-the-eu-market-301895530.html
Summer.76,
09.08.2023 22:30 Uhr
0
Accuray GAAP EPS of -$0.03 misses by $0.04, revenue of $118.3M misses by $3.44M
https://seekingalpha.com/news/4000416-accuray-gaap-eps-of-0_03-misses-0_04-revenue-of-118_3m-misses-3_44m
• Accuray press release (NASDAQ:ARAY): Q4 GAAP EPS of -$0.03 misses by $0.04.
• Revenue of $118.3M (+7.5% Y/Y) misses by $3.44M.
• The Company is introducing guidance for fiscal year 2024 as follows:
• Total revenue is expected in the range of $460 million to $470 million vs $451.05M consensus, representing a year-over-year growth range of 3% to 5%.
• Adjusted EBITDA is expected in the range of $27 million to $30 million.
Meistdiskutiert
|
Thema | ||
---|---|---|---|
1 | SAFE | +16,67 % | |
2 | Gme sinnvoller austausch der apes | +3,08 % | |
3 | Trading- und Aktien-Chat | ||
4 | GAMESTOP Hauptdiskussion | +3,08 % | |
5 | für alle, die es ehrlich meinen beim Traden. | ||
6 | Algreen SA | +28,57 % | |
7 | AMC ENTERTAINMENT Hauptdiskussion | +1,93 % | |
8 | BED BATH & BEYOND Hauptdiskussion | -28,27 % | |
9 | BYD Hauptdiskussion | +2,42 % | |
10 | EVOTEC Hauptdiskussion | -2,14 % | Alle Diskussionen |
Anzeige
Aktien
|
Thema | ||
---|---|---|---|
1 | SAFE | +16,67 % | |
2 | Gme sinnvoller austausch der apes | -0,37 % | |
3 | GAMESTOP Hauptdiskussion | -0,37 % | |
4 | Algreen SA | +28,57 % | |
5 | AMC ENTERTAINMENT Hauptdiskussion | +1,93 % | |
6 | BED BATH & BEYOND Hauptdiskussion | -28,27 % | |
7 | BYD Hauptdiskussion | +3,91 % | |
8 | EVOTEC Hauptdiskussion | -2,14 % | |
9 | Metasphere Labs Hauptdiskussion | +10,48 % | |
10 | Wonderfi Technologies Inc Hauptforum | ±0,00 % | Alle Diskussionen |